Taofeek K. Owonikoko, MD, PhD, discusses the emerging classifications of lung cancer, implementing appropriate molecular testing for patients, and the use of appropriate treatment for different subsets of lung cancer.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Describe and use the emerging classifications of lung cancer
- Implement appropriate molecular testing for patients
- Follow recommended guidelines for treatment options
- Implement the use of appropriate treatment for different subsets of lung cancer
Disclosures
Dr. Owonikoko has reported a relevant financial relationship with an entity producing health care goods or services.
Consultant: AtraZeneca, Ispen, Novartis
Stockholder: Cambium Oncology
All presenters' disclosures of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients is listed above. No other planners, members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh designates enduring material activity for a maximum of .75 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.
Release Date: 12/06/2021| Last Modified On: 12/06/2021 | Expires: 12/06/2022
Disclosure Description
- Ramalingam, et al, Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. PMID: 31751012.
- Mok, et al, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. PMID: 19692680.
- Horn, et al, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. PMID: 30280641
